30 results about "Neuroglial cells" patented technology

A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and / or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and / or treating a disease, disorder, and / or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.

The present invention relates to a forebrain assembloid that exhibits a maturity similar to that of the human brain, and a schizophrenia biomarker identified using the forebrain assembloid. More specifically, the present invention relates to: a method for preparing a forebrain assembloid; a forebrain assembloid having a single rosette structure that includes six cortical layers and cavities, the cortical layers including glial cells; a composition for diagnosing schizophrenia, comprising an agent for measuring the expression level of UCN, an agent for measuring the expression level of PTPRF, an agent for measuring the expression level of WNT11, and an agent for measuring the expression level of THBS4; and a kit comprising the composition for diagnosing schizophrenia.

The present application relates to reducing the adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, astrocyte loss, or white matter loss, in the brain of a subject. The present application also relates to rejuvenating glial progenitor cells or their progeny, or enhancing the developmental potential of glial progenitor cells or their progeny.

The present invention relates to a forebrain assembloid that exhibits maturity similar to that of the human brain and expresses ChR2 to enable optogenetic analysis and, more specifically, to: a method for producing a forebrain assembloid that enables optogenetic analysis; a forebrain assembloid produced by the method; and a forebrain assembloid having a single rosette structure, comprising six cortical layers and cavities, wherein the cortical layers include glial cells and uniformly express ChR2.

Described herein are methods and compositions for treating a disease, e.g. cancer (including solid tumors), using glial cells (e.g. microglia cells and / or astrocytes) and / or macrophages (e.g., CNS-associated macrophages) infected with an oncolytic virus (e.g., vaccinia virus). The methods and compositions provided herein demonstrate a synergistic anti-cancer effect.

The invention belongs to the field of biological medicine, and particularly relates to a medicine for promoting microglial cell M2 type polarization and application of the medicine. The drug provided by the invention contains Densiflorol B. The drug provided by the invention has the advantages that the drug effect is good; the medicine can promote M2 type polarization of microglial cells, and has protection and repair effects on damaged nerves.

The invention discloses application of ethyl caffeate in preparation of heart and nerve protection medicines, and belongs to the technical field of biological medicines. Models of rat embryo myocardial cell injury caused by oxygen-glucose deprivation and mouse microglial cell injury caused by lipopolysaccharide are respectively constructed, and related indexes such as inflammation, oxidative stress and cell apoptosis are evaluated; it is proved that ethyl caffeate has an obvious protection effect on ischemic and hypoxic myocardial cells and inflammation-damaged glial cells, and can be used for preparing heart and nerve protection drugs.

The application discloses a lactobacillus rhamnosus capable of significantly increasing the number of enteric neurons and neuroglial cells and an application thereof, and belongs to the field of microorganisms.The lactobacillus rhamnosus CCFM1360 has good activity, certain acid and alkali resistance and adhesion, can significantly increase the number of enteric neurons and neuroglial cells, repair intestinal barrier function, increase the content of SCFAs in colon contents, increase the number of Treg cells in mesenteric lymph nodes, reduce the expression level of inflammatory factors in colon tissues, reduce the intestinal inflammation level, and relieve the weakened intestinal motility disorder.

Disclosed is a use of artemether in preventing and treating Alzheimer's disease. Artemether is a safe and effective compound for treatment against malaria. Artemether activates an AMPK signaling pathway in the brain of a transgenic mouse model of Alzheimer's disease, improves learning and memory abilities in the mouse model, reduces neuron apoptosis in the brain, improves function of choline acetyltransferase, inhibits activity of glial cells, and reduces amyloid plaque deposition, neurofibrillary tangle, and neuron loss, thereby providing an experimental basis for clinical research on the treatment of Alzheimer's disease.

The invention discloses a composition for enhancing memory and improving cognitive function and application. The composition disclosed by the invention comprises acanthopanax, ginseng, Chinese wolfberry fruits, gastrodia elata, spina date seeds, poria cocos, Chinese yams, lotus seeds, gordon euryale seeds, mulberries, longan pulp, fresh ginger, walnut powder, egg protein powder, blueberry powder, raspberry powder, pumpkin seed powder, oat powder, spirulina powder, dark chocolate powder, a vitamin B group compound, gamma-aminobutyric acid, galactooligosaccharide and citric acid. According to the invention, a multi-channel and multi-target collaborative network is constructed by taking acanthopanax senticosus as a core, through multiple channels such as nerve regeneration, energy metabolism, oxidative stress, signal transduction, endocrine regulation and the like, different nodes such as neurons, neuroglial cells, cerebrovascular endothelium and the like are targeted, the overall optimization of the memory function is realized on the system level, and the memory function is optimized. The core idea of systematic biology of overall regulation and control is reflected, and the composition prepared from the composition has the effects of improving memory, learning ability and cognitive ability.

The invention provides a method for in-vitro detection of exogenous gene expression activity of AAV virus in nerve cells and an evaluation system. The method comprises the following steps: infecting N2A cranial nerve tumor cells by using AAV carrying a neuron-specific promoter or a glial cell-specific promoter and a reporter gene driven by the neuron-specific promoter or the glial cell-specific promoter; and detecting the level of a reporter gene transcript or a protein expressed by the reporter gene in the infected N2A cranial nerve tumor cell so as to detect the activity of the AAV expressing the exogenous gene. According to the method disclosed by the invention, the target gene expression driven by the CamKII promoter of the AAV9 serotype is tested by utilizing the N2A cranial nerve tumor cells, the problem that a suitable cell model is lacked in the prior art is solved, and a new tool and a new method are provided for AAV activity test in neurobiology research.

This invention belongs to the field of biology and discloses a method for co-culturing enteric glial cells (EGCs) and intestinal organoids. Primary cultured and purified enteric glial cells are digested and seeded onto the membrane of a Transwell chamber. Intestinal organoids are placed in individual Matrigel drops in a co-culture plate. The Transwell chambers are placed in the co-culture plate, and growth medium is added to ensure free exchange of the growth medium through the Transwell membrane. The EGC-organoid co-culture system obtained based on this method provides a model for studying diarrhea and intestinal health in large mammals. It also lays the research foundation for developing innovative intervention strategies targeting the enteric nervous system and provides a research model for further exploring the regulatory roles of nutrients or related genes in intestinal health.

The invention discloses a dual-targeting viscosity detection near-infrared fluorescence / photoacoustic probe as well as preparation and application thereof, and a probe ER-V2 with viscosity specific recognition capability is successfully designed and synthesized by taking trimethylbenzoindole as a core. The probe ER-V2 is based on a hemicyanine donor-pi-receptor (D-pi-A) structure, a p-toluene sulfonamide part is used for targeting endoplasmic reticulum, and an N, N-dimethylaminophenyl part is used for A beta plaque binding, so that precise double targeting is realized. The extended pi conjugation provides near-infrared emission, enhances viscosity sensitivity by limiting intramolecular rotation, and produces a strong photoacoustic signal. In combination with high sensitivity of near-infrared fluorescence and strong penetrating power of a photoacoustic technology in tissues, the probe ER-V2 can penetrate a blood brain barrier, realizes real-time and high-sensitivity near-infrared fluorescence / photoacoustic imaging in neuroglial cells and the brain of a mouse with the Alzheimer's disease, and has important significance on early diagnosis of the Alzheimer's disease. The fluorescent probe is expected to become a useful fluorescent tool for researching Alzheimer's disease and endoplasmic reticulum related diseases in the future.

The invention relates to a liquid dressing for skin and a preparation method of the liquid dressing. A film forming material of the liquid dressing comprises glial cell supernate. The neuroglial cells used in the invention are derived from neural stem cells which have been subjected to long-term in-vitro culture amplification, so that the obtained culture supernatant has the advantages of large scale, stable quality and mature technology, and a large number of liquid dressing products with stable and consistent quality standards can be provided in a short time; meanwhile, the supernate has good film-forming property and safety, contains a large number of human cell active components which are good in human body compatibility and beneficial to wound healing, and is suitable for large-scale batch production and application.

The invention relates to a phenanthrene type norditerpenoid, a preparation method thereof and an application of the phenanthrene type norditerpenoid in a medicine for preventing and treating neuroinflammation in the technical field of biological medicines, and the phenanthrene type norditerpenoid is extracted from Leucodendron hainanense and is a norditerpenoid component with a gem-dimethyl 6 / 6 / 6 tricyclic phenanthrene type structure. The extraction method comprises the following steps: firstly, extracting a dried medicinal material of Hainan acalypha australis with ethanol with the mass concentration of 95%, and then filtering, concentrating under reduced pressure and drying to obtain a 95% ethanol extract; adding water to disperse, and sequentially extracting with petroleum ether, ethyl acetate and n-butyl alcohol to obtain extracts of corresponding parts; and finally, performing chromatographic separation and purification on the ethyl acetate part. The phenanthrene type norditerpenoid disclosed by the invention can be used for inhibiting the release of an inflammatory factor NO of BV-2 neural microglial cells; the invention has important significance on the development of drugs for treating neuroinflammation diseases.

The application discloses a Bifidobacterium longum subsp. longum strain for regulating intestinal homeostasis and relieving intractable constipation and an application thereof, and belongs to the field of microorganisms. The strain CCFM1319 provided by the application can shorten the time of the first black stool of intractable constipation mice, significantly enhance the colon peristalsis ability of the intractable constipation mice, increase the expression level of the characteristic marker of enteric glial cells in the colon tissue, repair the intestinal nerve damage caused by intractable constipation, reduce the expression level of inflammatory factors in the colon tissue of the intractable constipation mice, relieve the inflammation of the intestinal immune barrier, reduce the pathological damage of the colon tissue, increase the expression amount of the tight junction protein in the colon tissue, repair the damage of the intestinal mechanical barrier, avoid excessive water absorption, be beneficial to the excretion of feces, regulate the intestinal chemical barrier, improve the intestinal microecological imbalance, make the intestinal flora structure tend to be healthy, and repair the damage of the intestinal biological barrier, so as to play a role in comprehensively relieving intractable constipation.

The invention relates to a liquid dressing for skin and a preparation method of the liquid dressing. A film forming material of the liquid dressing comprises glial cell supernate. The neuroglial cells used in the invention are derived from neural stem cells which have been subjected to long-term in-vitro culture amplification, so that the obtained culture supernatant has the advantages of large scale, stable quality and mature technology, and a large number of liquid dressing products with stable and consistent quality standards can be provided in a short time; meanwhile, the supernate has good film-forming property and safety, contains a large number of human cell active components which are good in human body compatibility and beneficial to wound healing, and is suitable for large-scale batch production and application.

The invention belongs to the technical field of biological medicine, and particularly relates to application of lactic acid in preparation of a neuron protective agent. Results of the invention show that the exogenous lactic acid can improve late-stage injury caused by HIE injury of newborn rats, and the neuroprotective effect of the exogenous lactic acid plays a role through a plurality of mechanisms; comprising the following steps: reducing excessive hyperplasia of microglial cells and astrocytes, regulating phenotypic polarization of the neuroglial cells, inhibiting neuroinflammatory response, reducing excessive synaptic phagocytosis mediated by the microglial cells and reducing a depolarization state of the astrocytes AQP4, so that neuron damage and behavioral defects of HIE newborn rats are relieved.

The application discloses a bifidobacterium that can significantly improve the expression of BDNF of a host and an application thereof, and belongs to the technical field of microorganisms. The bifidobacterium CCFM1359 provided by the application can effectively improve the levels of BDNF and its specific receptor TrkB in the colon of a mouse, can also increase the number of enteric glial cells, improve the content of excitatory neurotransmitter Ach in the colon, down-regulate the content of inhibitory neurotransmitter NO, and repair the enteric nervous system. Moreover, the bacteria can down-regulate the gene expression levels of TLR2 and TNF-alpha, up-regulate the gene expression level of IL-10, reduce the inflammation level in the colon, and regulate the intestinal motility. Therefore, in the future, a more personalized treatment scheme can be adopted for patients with damaged enteric nerves (including but not limited to intestinal motility disorders), and the application prospect is very considerable.

The present disclosure relates to methods of preventing, or delaying the progression of, death of neurons and / or microgliosis and / or astrogliosis that contributes to the death of neurons. The present disclosure also relates to methods of treating, preventing, or delaying the progression of, a synucleinopathy (e.g., Parkinson's disease). Also disclosed are related in vitro, ex vivo, and in vivo methods of identifying agents and / or compositions useful for preventing, or delaying the progression of, death of neurons and / or microgliosis and / or astrogliosis that contributes to the death of neurons and agents and / or compositions useful for treating, preventing, or delaying the progression of, a synucleinopathy. The agents and / or compositions of the present disclosure decrease the level and / or activity of a cis-regulatory element that propagates the misfolding and aggregation of proteins encoded by synucleinopathy-associated genes in neurons and / or glial cells.

The application discloses a lactobacillus paracasei for repairing intestinal nerves and an application thereof, and belongs to the field of microorganisms. The lactobacillus paracasei CCFM1321 provided by the application can significantly increase the number of intestinal nerve glial cells, improve the level of glial cell-derived neurotrophic factor GDNF and the expression of its receptor GFR alpha 1 / RET, and repair the damaged intestinal nervous system of mice. The lactobacillus paracasei can down-regulate the over-activation of Toll-like receptor 2 (TLR2), reduce the expression of inhibitory neurotransmitters, increase the expression of serotonin 5-HT and its receptor 5-HT 2B , and has the effect of protecting the intestinal nervous system. Moreover, the lactobacillus paracasei can reduce the inflammation level in the colon tissue caused by the damage of intestinal nerves, improve the pathological damage of the colon tissue, and relieve the intestinal motility disorder. Therefore, a more personalized treatment scheme can be adopted for gastrointestinal diseases caused by the abnormal intestinal nervous system, and the application prospect is considerable.

This invention relates to a liquid dressing for skin and its preparation method. The film-forming material of the liquid dressing comprises glial cell supernatant. The glial cells used in this invention are derived from neural stem cells that have achieved long-term in vitro culture and expansion. This allows for the production of culture supernatant with advantages such as large-scale production, stable quality, and mature technology. It can provide a large quantity of liquid dressing products with consistent quality standards in a short time. Furthermore, the supernatant exhibits good film-forming properties and safety, and contains a large number of biocompatible, wound-healing, and bioactive human cell components, making it suitable for large-scale mass production and application.

The invention discloses application of ergothioneine in promoting neural function recovery after spinal cord injury. The new application of the ergothioneine comprises inhibiting senescence of tissues or cells in a central nervous system after spinal cord injury, treating mitochondrial dysfunction of glial cells after spinal cord injury, promoting spinal cord injury repair and inhibiting spinal cord tissue inflammation after spinal cord injury. The invention reveals for the first time that ergothioneine significantly promotes spinal nerve regeneration, improves neurological functions, alleviates inflammatory response after aging and protects spinal cord tissues by regulating immune cell mitochondrial function-cell aging axis, and provides an innovative strategy for spinal cord injury treatment. The ergothioneine synergistically intervenes in secondary neurodegenerative diseases after spinal cord injury by protecting mitochondrial functions and immune dual pathways, and a brand new direction is provided for SCI treatment.

A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and / or (2) at least 5% of all of the glial cells in the white matter of the brain and / or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.

The present invention provides compositions and methods for inhibiting the autoimmune component of neurodegenerative diseases and thereby providing a therapeutic effect to patients suffering from such diseases. The compositions and methods comprise immunosuppressive moieties, such as regulatory T cells (Tregs) and proteins expressed by Tregs coupled to a chimeric antigen receptor or that specifically bind to one or more glial cell markers. Therapeutically effective doses of the compounds for treating neurodegenerative diseases, including progressive supranuclear palsy (PSP), Parkinson's disease (PD), Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), and prion diseases, are disclosed.

The invention relates to the field of senescence and systematic dynamics research, in particular to a glial cell marker set of a brain senescence critical point and application of the glial cell marker set in senescence mechanism research. 45 healthy human brain samples of 29-94 years old are analyzed through a single cell transcriptome, it is found for the first time that 56-60 years old are brain aging critical points, and a dynamic network marker (DNB) set composed of microglial cells, astrocytes and oligodendrocytes is identified and comprises key molecules mTOR, PADI2, JAK1, ARHGEF11 and KAZN. The marker set realizes early warning of an aging critical point by detecting the following characteristics: (1) PASP-GPR37L1 / PASP-GPR37 communication between glial cells is obviously weakened; (2) the activity of the neuron-microglial cell CX3CL1-CX3CR1 / IL34-CSF1R pathway is reduced, and the activity of the neuron-microglial cell pathway is reduced; and (3) DNB molecular expression fluctuation peak. The marker set disclosed by the invention can be used for developing a brain aging early warning kit and screening intervention targets.

The present invention provides compositions and methods for inhibiting the autoimmune component of neurodegenerative diseases and thereby providing a therapeutic effect to patients suffering from such diseases. The compositions and methods comprise immunosuppressive moieties, such as regulatory T cells (Tregs) and proteins expressed by Tregs coupled to a chimeric antigen receptor or proteins that specifically bind to one or more glial cell markers. Therapeutically effective doses of the compounds for treating neurodegenerative diseases, including progressive supranuclear palsy (PSP), Parkinson's disease (PD), Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), and prion diseases, are disclosed.

A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and / or (2) at least 5% of all of the glial cells in the white matter of the brain and / or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.

The present invention provides a composition for promoting proliferation, differentiation and maturation of neural stem cells, promoting activation of small glial cells, and promoting activation of astrocytes. It is found that a composition comprising lactic acid bacteria (in particular enterococcus faecium), clostridium butyricum (in particular clostridium butyricum), and saccharifying bacteria (in particular bacillus subtilis) has an effect of increasing the number of neural stem cells in a resting period, an effect of promoting differentiation and maturation of neural stem cells into nerve cells, an effect of promoting proliferation of neural stem cells, and an effect of promoting proliferation of neural stem cells. The present invention relates to an effect of promoting maturation of immature nerve cells, an effect of promoting activation of small glial cells, an effect of promoting activation of astrocytes, an effect of promoting generation of adult nerves, an effect of maintaining brain function homeostasis, and an effect of maintaining and / or improving memory and / or learning ability.